{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T13:08:46Z","timestamp":1754399326018,"version":"3.40.4"},"reference-count":29,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,6,9]]},"abstract":"<jats:p>Budd-Chiari syndrome (BCS) is caused by hepatic venous outflow obstruction commonly seen with myeloproliferative neoplasms (MPNs). Polycythaemia vera (PV) is a very rare MPN in childhood. This is the youngest reported patient diagnosed with PV and BCS secondary to<jats:italic>JAK V617F<\/jats:italic>mutation.<\/jats:p><jats:p>A 26-month-old girl was admitted with a 5-month history of abdominal distension, hepatosplenomegaly and ascites. Imaging studies revealed occlusion of the right hepatic vein and marked attenuation of the middle and left hepatic veins. BCS was diagnosed after excluding other causes of chronic liver disease. Mandatory prothrombotic workup revealed underlying PV.<\/jats:p><jats:p>Partial recanalisation of hepatic veins occurred following anticoagulation therapy and PV was well controlled by pegylated interferon and hydroxycarbamide until she developed nephrotic syndrome, likely secondary to pegylated interferon. Therefore, treatment was modified to ruxolitinib, a novel-JAK-2 inhibitor; the therapy has been effective for almost 20 months with a good response and has no side effects.<\/jats:p>","DOI":"10.1136\/bcr-2017-220377","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T08:40:29Z","timestamp":1500021629000},"page":"bcr-2017-220377","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome"],"prefix":"10.1136","volume":"2017","author":[{"given":"Mehmet Enes","family":"Coskun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Height","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nedim","family":"Hadzic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,7,14]]},"reference":[{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.1","DOI":"10.1136\/postgradmedj-2015-133402"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.2","DOI":"10.1002\/(SICI)1099-1069(199711)15:4<173::AID-HON610>3.0.CO;2-K"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.3","DOI":"10.1007\/s00277-009-0758-y"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.4","DOI":"10.1182\/blood-2013-03-460154"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.5","DOI":"10.1158\/1078-0432.CCR-12-0284"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.6","DOI":"10.1038\/leu.2012.12"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.7","DOI":"10.1002\/pbc.23409"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.8","DOI":"10.1007\/s12308-015-0256-1"},{"key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.9","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s40265-015-0470-2","article-title":"Ruxolitinib: a Review in Polycythaemia Vera","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.10","DOI":"10.1182\/blood-2011-08-371328"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.11","DOI":"10.1200\/JCO.2010.31.8436"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.12","DOI":"10.1111\/j.1365-2141.2010.08122.x"},{"key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.20906","article-title":"Stem cell transplantation for polycythemia vera","volume":"50","author":"Reinhard","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.14","first-page":"p. 337","article-title":"Allogeneic bone marrow transplantation for an adolescent with polycythemia vera","volume":"13","author":"Stobart","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.15","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.clml.2015.02.013","article-title":"New therapeutic approaches in Polycythemia Vera","volume":"15 Suppl","author":"Falchi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.16","DOI":"10.2165\/00063030-200822050-00004"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.17","DOI":"10.1182\/blood-2008-03-143537"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.18","DOI":"10.1200\/JCO.2009.23.6075"},{"key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.19","first-page":"p. 27","article-title":"[Polycytemia vera in an 11-year old girl]","volume":"137","author":"Nagy","year":"1996","journal-title":"Orvosi hetilap"},{"key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.20","first-page":"p. 705","article-title":"[Interferon alpha in the treatment of polycythemia vera in a 13-year-old girl]","volume":"71","author":"Olpinski","year":"1996","journal-title":"Pediatr Pol"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.21","DOI":"10.1111\/j.1365-2141.2008.07220.x"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.22","DOI":"10.1002\/1097-0142(19860415)57:8+<1709::AID-CNCR2820571315>3.0.CO;2-F"},{"key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical toxicity of interferons in Cancer patients: a review","volume":"4","author":"Quesada","year":"1986","journal-title":"J Clin Oncol"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.24","DOI":"10.1111\/j.1478-3231.2006.01361.x"},{"key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0272-6386(12)70268-8","article-title":"Unusual glomerular lesion in a patient receiving long-term interferon alpha","volume":"20","author":"Lederer","year":"1992","journal-title":"Am J Kidney Dis"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.26","DOI":"10.1002\/cncr.28441"},{"doi-asserted-by":"crossref","unstructured":"Verstovsek S , Kiladjian JJ , Griesshammer M , et al . Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial.. Journal of Clinical Oncology 2014;32.","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.27","DOI":"10.1200\/jco.2014.32.15_suppl.7026"},{"key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.28","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00280-016-3012-z","article-title":"Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib","volume":"77","author":"Bryan","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"doi-asserted-by":"publisher","key":"2025042712074068000_2017.jul14_1.bcr-2017-220377.29","DOI":"10.1002\/pbc.25575"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-220377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T19:07:50Z","timestamp":1745780870000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-220377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,14]]},"references-count":29,"alternative-id":["10.1136\/bcr-2017-220377"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-220377","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2017,7,14]]}}}